Mass spectral analysis of medicinal pyrazolidinediones. 1974

R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy

UI MeSH Term Description Entries
D010113 Oxyphenbutazone A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27) Hydroxyphenylbutazone,Diflamil,Oxyphenylbutazone,Tanderil
D010653 Phenylbutazone A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS. Diphenylbutazone,Fenilbutazon,Butacote,Butadion,Butadione,Butapirazol,Butapyrazole,Butazolidin
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D003903 Deuterium The stable isotope of hydrogen. It has one neutron and one proton in the nucleus. Deuterons,Hydrogen-2,Hydrogen 2
D013058 Mass Spectrometry An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. Mass Spectroscopy,Spectrometry, Mass,Spectroscopy, Mass,Spectrum Analysis, Mass,Analysis, Mass Spectrum,Mass Spectrum Analysis,Analyses, Mass Spectrum,Mass Spectrum Analyses,Spectrum Analyses, Mass
D013442 Sulfinpyrazone A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. Sulfoxyphenylpyrazolidin,Anturan,Anturane,Apo-Sulfinpyrazone,Nu-Sulfinpyrazone,Sulphinpyrazone,Apo Sulfinpyrazone,Nu Sulfinpyrazone

Related Publications

R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
March 1971, Biochemistry,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
January 1973, Journal of medicinal chemistry,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
January 2004, Annual review of biophysics and biomolecular structure,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
January 2016, Evidence-based complementary and alternative medicine : eCAM,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
April 1978, Journal of pharmaceutical sciences,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
September 2017, Journal of the American Society for Mass Spectrometry,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
June 1969, Mitteilungen. Deutsche Pharmazeutische Gesellschaft,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
May 1998, Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
January 1991, Journal of chromatography,
R A Locock, and R E Moskalyk, and L G Chatten, and L M Lundy
May 1977, Journal of pharmaceutical sciences,
Copied contents to your clipboard!